

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 14, 2023
PDL Changes Effective Date: April 1, 2023



The following changes will be made to the Preferred Drug List (PDL), effective April 1, 2023, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

| NEW PREFERRED DRUGS | |
|----------------------------|--|
| THERAPEUTIC CLASS | RECOMMENDED for PREFERRED STATUS |
| COLONY STIMULATING FACTOR | FYLNETRA (pegfilgrastim) |
| POTASSIUM REMOVING AGENTS | LOKELMA (sodium zirconium cyclosilicate) |

| NEW NON-PREFERRED DRUGS | |
|--------------------------------|---|
| THERAPEUTIC CLASS | RECOMMENDED for NON-PREFERRED STATUS |
| ANTICONVULSANTS | ZONISADE (zonisamide suspension) |
| ANTICONVULSANTS | ZTALMY (ganaxolone) |
| ANTIDEPRESSANTS | AUVELITY(dextromethorphan-bupropion) |
| ANTIFUNGAL (ORAL) | VIVJOA (oteseconazole) |
| BPH AGENTS | ENTADFI (finasteride / tadalafil) |
| COLONY STIMULATING FACTOR | ZIEXTENZO (pegfilgrastim) |
| CYTOKINE & CAM ANTAGONISTS | SOTYKTU(deucravacitinib) |
| CYTOKINE & CAM ANTAGONISTS | SPEVIGO(spesolimab-sbzo) |
| INTRANASAL RHINITIS AGENTS | RYALTRIS NASAL (olopatadine/mometasone) |
| POTASSIUM REMOVING AGENTS | sodium polystyrene sulfonate |
| POTASSIUM REMOVING AGENTS | SPS ENEMA (sodium polystyrene sulfonate) |
| POTASSIUM REMOVING AGENTS | SPS SUSPENSION (sodium polystyrene sulfonate) |
| POTASSIUM REMOVING AGENTS | VELTASSA (patiromer calcium sorbitex) |
| PULMONARY ANTIHYPERTENSIVES | TADLIQ (tadalafil suspension) |